Scientific Journals Articles Nov 2014

Articles can be sourced by searching with the doi.
Journal membership is required to access some of the papers, others are free to access.


 

Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma

Vassiliki A. Boussiotis, M.D., Ph.D.

November 19, 2014
DOI: 10.1056/NEJMe1413061


67-kDa Laminin Receptor-dependent Protein Phosphatase 2A (PP2A) Activation Elicits Melanoma-specific Antitumor Activity Overcoming Drug Resistance

Shuntaro Tsukamoto, Yuhui Huang, Daisuke Umeda, Shuhei Yamada, Shuya Yamashita, Motofumi Kumazoe, Yoonhee Kim, Motoki Murata, Koji Yamada and Hirofumi Tachibana

  1. Biol. Chem. 2014, 289:32671-32681.

originally published online October 7, 2014
doi: 10.1074/jbc.M114.604983


?-Actinin-4 Is Required for Amoeboid-type Invasiveness of Melanoma Cells*

  1. Hanshuang Shao,Shaoyan LiSimon C. Watkins and Alan Wells,

The Journal of Biological Chemistry, 2014, 289: 32717-32728.

First Published onOctober 8, 2014,
5November 21, 2014
doi:10.1074/jbc.M114.57918


 

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. A Randomized Clinical Trial

  1. Stephen Hodi, MD1; Sandra Lee, ScD2,3; David F. McDermott, MD4,5; Uma N. Rao, MD6; Lisa H. Butterfield, PhD7; Ahmad A. Tarhini, MD, PhD7; Philip Leming, MD8,9; Igor Puzanov, MD10; Donghoon Shin, SM2,3; John M. Kirkwood, MD7

JAMA. 2014;312(17):1744-1753.
doi:10.1001/jama.2014.13943.


 

Therapy Preferences in Melanoma Treatment – Willingness to Pay and Preference of Quality versus Length of Life of Patients, Physicians and Healthy Controls

  • Ramona Krammer, Lucie Heinzerling
  • Published: November 04, 2014

PLOS one
DOI: 10.1371/journal.pone.0111237


 

Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition

Patricia A. Possik, Judith Müller, Carmen Gerlach5, Juliana C.N. Kenski,, Xinyao Huang, Aida Shahrabi, Oscar Krijgsman, Ji-Ying Song, Marjon A. Smit6,Bram Gerritsen7, Cor Lieftink, Kristel Kemper, Magali Michaut, Roderick L. Beijersbergen, Lodewyk Wessels, Ton N. Schumacher, Daniel S. Peeper

Cell Reports
DOI: http://dx.doi.org/10.1016/j.celrep.2014.10.024


 

Melanoma progression is associated with NK cell exhaustion

Ines Pires da Silva,  Anne Gallois, Sonia Jimenez-Baranda, Ana Anderson, Vijay Kuchroo, Iman Osman, Nina Bhardwaj*

From Society for Immunotherapy of Cancer 29th Annual Meeting, National Harbor, MD, USA. 6-9 November 2014

Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):O6
doi:10.1186/2051-1426-2-S3-O6


 

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma

  1. Parakh Bsc MbChB*,C. Murphy MBBS, D. Lau MBBS FRACP, J. S. Cebon MBBS PhD FRACP and M. C. Andrews Bsc (Honours) MBBS FRACP

Article first published online: 10 NOV 2014

Journal of Clinical Pharmacy and Therapeutics
DOI: 10.1111/jcpt.12229


 

CYP24A1 Expression Inversely Correlates with Melanoma Progression: Clinic-Pathological Studies

Anna A. Bro?yna, Cezary Jochymski, Zorica Janjetovic, Wojciech Jó?wicki , Robert C. Tuckey and Andrzej T. Slominski

Open Access Int. J. Mol. Sci. 2014, 15, 19000-19017;
doi:10.3390/ijms151019000


 

Rapid Evolution of Combination Therapy in Melanoma

Brendan D. Curti, M.D.

N Engl J Med 2014; 371:1929-1930
November 13, 2014
DOI: 10.1056/NEJMe1411158

 


 

Nivolumab in Previously Untreated Melanoma without BRAFMutation

Caroline Robert, M.D., Ph.D., Georgina V. Long, M.D., Ph.D., Benjamin Brady, M.D., Caroline Dutriaux, M.D., Michele Maio, M.D., Laurent Mortier, M.D., Jessica C. Hassel, M.D., Piotr Rutkowski, M.D., Ph.D., Catriona McNeil, M.D., Ph.D., Ewa Kalinka-Warzocha, M.D., Ph.D., Kerry J. Savage, M.D., Micaela M. Hernberg, M.D., Ph.D., Celeste Lebbé, M.D., Ph.D., Julie Charles, M.D., Ph.D., Catalin Mihalcioiu, M.D., Vanna Chiarion-Sileni, M.D., Cornelia Mauch, M.D., Ph.D., Francesco Cognetti, M.D., Ana Arance, M.D., Ph.D., Henrik Schmidt, M.D., D.M.Sc., Dirk Schadendorf, M.D., Helen Gogas, M.D., Lotta Lundgren-Eriksson, M.D., Christine Horak, Ph.D., Brian Sharkey, Ph.D., Ian M. Waxman, M.D., Victoria Atkinson, M.D., and Paolo A. Ascierto, M.D.

November 16, 2014
DOI: 10.1056/NEJMoa1412082

Menu